title: Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel.
abstract: OBJECTIVE
  Single nucleotide polymorphisms (SNPs) of certain genes involved in drug metabolism correlate with survival.
  
  
  METHODS
  We evaluated the presence of SNPs in six genes (CYP2C8, GSTT1, GSTP1, MDR1-57, MDR1-62, and ERCC1) and the response rate (RR), time to progression (TTP), and overall survival (OS) of advanced head and neck cancer patients treated with weekly paclitaxel.
  
  
  RESULTS
  SNPs in CYP2C8, MDR1-57, and MDR1-62 genes were more frequent than wild-type genes in our patients. RR was 45% (21/47), and median TTP in responders was 5.1 months. OS for all patients was 5.6 months. Response was higher in SNPs of MDR1-62, MDR1-57, or in two or more accumulated genes than in those with wild-type genes. OS was significantly longer in patients with two or more accumulated SNPs (P = .039).
  
  
  CONCLUSIONS
  Response rate and OS were significantly higher in patients with two or more accumulated SNPs.
authors.affiliation: Oncology Department, Institut Clinic de Malalties Hemato-Oncològiques, Hospital Clinic, University of Barcelona, Spain.
authors.forename: Juan J
authors.initials: JJ
authors.lastname: Grau
authors.forename: Miguel
authors.initials: M
authors.lastname: Caballero
authors.forename: Marc
authors.initials: M
authors.lastname: Campayo
authors.forename: Sonia
authors.initials: S
authors.lastname: Jansa
authors.forename: Mauricio
authors.initials: M
authors.lastname: Vargas
authors.forename: Llucia
authors.initials: L
authors.lastname: Alós
authors.forename: Mariano
authors.initials: M
authors.lastname: Monzo
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D016001:Confidence Intervals; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004720:Endonucleases / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D005819:Genetic Markers / Q000235:genetics*; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D009687:Nuclear Proteins / Q000235:genetics; D017239:Paclitaxel / Q000008:administration & dosage*; D010166:Palliative Care; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011336:Probability; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D005819:Genetic Markers; D009687:Nuclear Proteins; D004720:Endonucleases; D017239:Paclitaxel